Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
6 ways to take back your motivation
Uncertainty about the future, being distant from friends, challenges with mental and physical health, and constantly staying in the same environment have all been ...
Read MoreThree types of plants that will thrive in your kitchen
There’s nothing like a little indoor greenery to brighten up your home, especially if you live in an apartment where there’s no space for ...
Read More5 Surprising myths about vitamin D
In the article we wrote about the telltale signs that your body needs more vitamin D, we pointed out that around 42 percent of ...
Read MoreAn “exercise pill” could be in our reach
Exercise is necessary for maintaining physical and mental health, and improving our quality and length of life. But for people who find it difficult ...
Read More
